Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,351,882 papers from all fields of science
Search
Sign In
Create Free Account
PARP2 protein, human
Known as:
PARP-2 protein, human
, PARP2
, NAD(+) ADP-Ribosyltransferase 2
Expand
Poly [ADP-ribose] polymerase 2 (583 aa, ~66 kDa) is encoded by the human PARP2 gene. This protein is involved in the initiation of DNA repair.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Base Excision Repair
Cell Nucleus
DNA Repair
DNA Repair Gene
Expand
Broader (1)
Poly(ADP-ribose) Polymerases
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Qin Zhou
,
M. Ji
,
+5 authors
Xiaoguang Chen
Biochemical Pharmacology
2016
Corpus ID: 12981621
2015
2015
A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer…
J. Litton
,
J. Blum
,
+9 authors
W. Eiermann
2015
Corpus ID: 76217439
TPS1107 Background: Poly-ADP-ribose polymerase (PARP) represents a family of enzymes of which at least two (PARP1 and PARP2) play…
Expand
Highly Cited
2012
Highly Cited
2012
Cell Death and Autophagy under Oxidative Stress: Roles of Poly(ADP-Ribose) Polymerases and Ca2+
P. Wyrsch
,
C. Blenn
,
Jessica J. Bader
,
F. Althaus
Molecular and Cellular Biology
2012
Corpus ID: 35445211
ABSTRACT On the cellular level, oxidative stress may cause various responses, including autophagy and cell death. All of these…
Expand
Review
2011
Review
2011
PARP inhibitors--current status and the walk towards early breast cancer.
J. Glendenning
,
A. Tutt
Breast
2011
Corpus ID: 3337985
2011
2011
Phase I trial of veliparib, (ABT-888), a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors.
Antoinette R. Tan
,
Deborah Toppmeyer
,
+9 authors
R. DiPaola
Journal of Clinical Oncology
2011
Corpus ID: 13552359
3041 Background: Veliparib is a potent, oral inhibitor of PARP-1 and PARP-2. We previously reported phase I results of veliparib…
Expand
2010
2010
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
L. Tentori
,
Alessia Muzi
,
+10 authors
G. Graziani
Current Cancer Drug Targets
2010
Corpus ID: 21633593
We recently demonstrated that poly(ADP-ribose) polymerase (PARP)-1 is involved in angiogenesis and tumour aggressiveness. In this…
Expand
2010
2010
Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
A. Tan
,
D. Gibbon
,
+7 authors
R. DiPaola
2010
Corpus ID: 78629699
3000 Background: ABT-888 is a potent, oral inhibitor of PARP-1 and PARP-2. In preclinical studies, ABT-888 enhances the…
Expand
Review
2006
Review
2006
PARP-2: Structure-Function Relationship
V. Schreiber
,
M. Ricoul
,
+9 authors
G. Murcia
2006
Corpus ID: 83117502
Poly(ADP-ribosyl)ation is an immediate DNA damage-dependent posttranslational modification of histones and other nuclear proteins…
Expand
Highly Cited
2004
Highly Cited
2004
Poly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break Resealing*
M. Malanga
,
F. Althaus
Journal of Biological Chemistry
2004
Corpus ID: 20073681
Regulating the topological state of DNA is a vital function of the enzyme DNA topoisomerase I. However, when acting on damaged…
Expand
2003
2003
Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage.
E. Meli
,
Marilena Pangallo
,
+4 authors
F. Moroni
Toxicology Letters
2003
Corpus ID: 20232810
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE